title: [Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series].
abstract: BACKGROUND
  This article reports about the use of a combined photodynamic therapy (PDT) and intravitreal injection of bevacizumab as a treatment option in nine patients with chronic central serous chorioretinopathy (CSC).
  
  
  METHODS
  A total of nine male patients with chronic CSC were treated with standard PDT laser treatment with verteporfin and intravitreal injection of bevacizumab administered within 24 h. Before and 1, 3, 6, 9 and 12 months after treatment the results of visual acuity, fluorescein angiography (FA) and optical coherence tomography (OCT) examinations were documented.
  
  
  RESULTS
  All patients showed an improvement in visual acuity of 1-4 ETDRS lines. Mean visual acuity increased from baseline 20 / 40 to 20 / 25 after 3 months. FA and OCT findings showed a restitution of leakages and subretinal fluid in all cases. After 6-12 months follow-up 8 patients had ongoing improvement in vision without recurrence of CSC.
  
  
  CONCLUSIONS
  The combination of PDT with bevacizumab in this case series appears to be an effective and safe therapy combination which is suitable as a therapeutic option for patients with chronic CCS without a tendency to recovery.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland. Mathias.Maier@mri.tum.de
authors.forename: M
authors.initials: M
authors.lastname: Maier
authors.forename: V
authors.initials: V
authors.lastname: Valet
authors.forename: N
authors.initials: N
authors.lastname: Feucht
authors.forename: C P
authors.initials: CP
authors.lastname: Lohmann
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1159-66
references.pmid: 21448811
references.citation: Retina. 2003 Dec;23(6):752-63
references.pmid: 14707823
references.citation: Klin Monbl Augenheilkd. 2006 May;223(5):372-5
references.pmid: 16705507
references.citation: Retina. 2010 Jan;30(1):100-6
references.pmid: 20010322
references.citation: Retina. 2009 Nov-Dec;29(10):1469-73
references.pmid: 19898183
references.citation: Retina. 2007 Sep;27(7):943-6
references.pmid: 17891021
references.citation: Ophthalmologe. 2010 May;107(5):479-92; quiz 493
references.pmid: 20454897
references.citation: Retina. 2002 Feb;22(1):25-32
references.pmid: 11884874
references.citation: Acta Ophthalmol. 2008 Mar;86(2):126-45
references.pmid: 17662099
references.citation: Ophthalmology. 2005 Dec;112(12):2088-94
references.pmid: 16325707
references.citation: Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 Sep-Oct;83(5):893-906
references.pmid: 563122
references.citation: Ophthalmologe. 2000 Aug;97(8):527-31
references.pmid: 10994328
references.citation: Int Ophthalmol. 2010 Apr;30(2):175-81
references.pmid: 19183854
references.citation: Ophthalmology. 2002 Sep;109(9):1723-5
references.pmid: 12208723
references.citation: Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4473-80
references.pmid: 14507895
references.citation: Retina. 1987 Summer;7(2):111-31
references.pmid: 3306853
references.citation: Ophthalmology. 2010 Sep;117(9):1792-9
references.pmid: 20472289
references.citation: Ophthalmologe. 2006 Oct;103(10):850-5
references.pmid: 16937094
references.citation: Br J Ophthalmol. 2003 Jun;87(6):709-12
references.pmid: 12770966
references.citation: Am J Ophthalmol. 2010 Mar;149(3):361-363
references.pmid: 20172062
references.citation: Br J Ophthalmol. 2005 May;89(5):562-4
references.pmid: 15834085
references.citation: Acta Ophthalmol. 2011 May;89(3):e293-4
references.pmid: 20346078
references.citation: Curr Eye Res. 2010 Feb;35(2):91-8
references.pmid: 20136418
references.citation: Br J Ophthalmol. 2011 Apr;95(4):514-7
references.pmid: 20644214
references.citation: Am J Ophthalmol. 2002 Jun;133(6):787-93
references.pmid: 12036670
references.citation: Br J Ophthalmol. 1988 Nov;72(11):829-34
references.pmid: 3061449
references.citation: Arch Ophthalmol. 1974 Apr;91(4):247-50
references.pmid: 4621147
references.citation: Ophthalmic Surg Lasers Imaging. 2010 Apr 02;:1-3
references.pmid: 20429499
references.citation: Arch Ophthalmol. 1999 Aug;117(8):1028-34
references.pmid: 10448745
references.citation: Ann Acad Med Singap. 2006 Jul;35(7):496-9
references.pmid: 16902727
references.citation: Ophthalmologica. 2007;221(5):282-91
references.pmid: 17728549
references.citation: Br J Ophthalmol. 2003 Dec;87(12):1453-8
references.pmid: 14660450